Q&A

Minimizing Bias When Blinding And Masking Drug Products

Source: Catalent
Pills Medication

Overcoming complex blinding and masking challenges in clinical trials requires a balance of strategy and adaptability. When conducting clinical trials, one of the most significant dangers to success is the presence of bias, which can be minimized using appropriate blinding and masking approaches. Dr. Paul Ingram, Global Director, Strategic Development and Innovation, Clinical Supply Services at Catalent Pharma Solutions, discusses the importance of blinding treatment allocations to patients and investigators in clinical studies, as well as physically masking products that are being tested.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: